Company intelligence / Profile preview

TianTi Biotherapeutics

Suzhou, Jiangsu, Chinattibio.com ↗

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

TianTi Biotherapeutics has not yet reported clinical results. The company’s pipeline consists of preclinical and discovery-stage antibody therapeutics targeting oncology and rare diseases. Their proprietary AbLink™ platform enables deep mining of the natural immune repertoire to identify rare therapeutic antibody candidates with high functional potential. No clinical trial data or approvals have been reported as of May 2025.

Therapeutic areas: OncologyRare Diseases
Modalities: Monoclonal antibodies (mAbs)VHH (single-domain antibodies/nanobodies)Therapeutic antibodies
Industry: Biotech

Beyond the preview

Go deeper on TianTi Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TianTi Biotherapeutics.

Explore the full profile